CAVEI recommendation on incorporation of a monoclonal antibody for passive immunization against respiratory syncytial virus in infants in the Program National Immunization

The CAVEI responds to the request of the National Immunization Program (PNI) of the Ministry of Health (MINSAL) received on July 4, 2023 to evaluate the incorporation of a new monoclonal antibody with long half-life against the respiratory virus syncicial in this Program. In this document, CAVEI analyzes the evidence available on efficacy and safety of the monoclonal antibody nirsevimab, background on cost effectiveness and international recommendations.